Open AccessPre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer
Author(s) -
Wei Wang,
Jin Gu,
Yanxia Liu,
Xiaoxu Liu,
Lei Jiang,
Changfen Wu,
Jing Liu
Publication year - 2022
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s359968
Subject(s) - medicine , proportional hazards model , biomarker , ovarian cancer , oncology , adjuvant therapy , cohort , univariate analysis , lymphocyte , multivariate analysis , stage (stratigraphy) , cancer , biology , paleontology , biochemistry
The novel CRP-albumin-lymphocyte (CALLY) index is an improved immunonutritive scoring system, based on serum C-reactive protein (CRP), serum albumin, and the lymphocyte count. It has been determined as a prognostic index for patients with hepatocellular carcinoma. This study was conducted to explore the prognostic value of the CALLY index in patients with epithelial ovarian cancer (EOC) undergoing surgery.